| [P4–133]: DIFFERENTIAL VALUE OF PLASMA TAU AS A BIOMARKER FOR ALZHEIMER'S DISEASE AND CHRONIC TRAUMATIC BRAIN INJURY S Fossati, JR Cejudo, L Debure, E Pirraglia, L Glodzik, RS Osorio, J Chen, ... Alzheimer's & Dementia 13 (7S_Part_27), P1307-P1307, 2017 | 4 | 2017 |
| 2014 Report on the milestones for the US national plan to address Alzheimer's disease Alzheimer's Association National Plan Milestone Workgroup, KN Fargo, ... Alzheimer's & Dementia 10, S430-S452, 2014 | 71 | 2014 |
| A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia M Haas, AS Unis, J Armenteros, MD Copenhaver, JA Quiroz, SF Kushner Journal of child and adolescent psychopharmacology 19 (6), 611-621, 2009 | 162 | 2009 |
| A double-blind, placebo-controlled, dose ranging study to evaluate the efficacy and tolerability of carisbamate (RWJ-333369) as adjunctive therapy in patients with refractory … RE Faught, WE Rosenfeld, GL Holmes, G Novak, AJ Greenspan, M Haas, ... Epilepsia 48 (6), 330, 2007 | 4 | 2007 |
| A framework to advance biomarker development in the diagnosis, outcome prediction, and treatment of traumatic brain injury EA Wilde, IB Wanner, K Kenney, J Gill, JR Stone, S Disner, C Schnakers, ... Journal of neurotrauma 39 (7-8), 436-457, 2022 | 43 | 2022 |
| A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders M Reyes, J Buitelaar, P Toren, I Augustyns, M Eerdekens American Journal of Psychiatry 163 (3), 402-410, 2006 | 190 | 2006 |
| Alzheimer's disease research and development: a call for a new research roadmap HH Feldman, M Haas, S Gandy, DD Schoepp, AJ Cross, R Mayeux, ... Annals of the New York Academy of Sciences 1313 (1), 1-16, 2014 | 53 | 2014 |
| An open-label, multicenter evaluation of the long-term safety and efficacy of risperidone in adolescents with schizophrenia G Pandina, S Kushner, K Karcher, M Haas Child and adolescent psychiatry and mental health 6 (1), 1-15, 2012 | 19 | 2012 |
| Big data to smart data in Alzheimer's disease: Real-world examples of advanced modeling and simulation M Haas, D Stephenson, K Romero, MF Gordon, N Zach, H Geerts, ... Alzheimer's & Dementia 12 (9), 1022-1030, 2016 | 33 | 2016 |
| Big data to smart data in Alzheimer's disease: The brain health modeling initiative to foster actionable knowledge H Geerts, PA Dacks, V Devanarayan, M Haas, ZS Khachaturian, ... Alzheimer's & Dementia 12 (9), 1014-1021, 2016 | 78 | 2016 |
| Build Back Brainier: Base Policies on Brain Science A Systemic Recovery, 91-105, 2022 | | 2022 |
| Carisbamate as adjunctive treatment of partial onset seizures in adults in two international, randomized, placebo-controlled trials MR Sperling, A Greenspan, J Cramer, P Kwan, R Kalviainen, JJ Halford, ... Epilepsia 49, 106-107, 2008 | 4 | 2008 |
| Carisbamate as adjunctive treatment of partial onset seizures in adults in two randomized, placebo‐controlled trials MR Sperling, A Greenspan, JA Cramer, P Kwan, R Kälviäinen, JJ Halford, ... Epilepsia 51 (3), 333-343, 2010 | 45 | 2010 |
| Chemically induced, activity-independent LTD elicited by simultaneous activation of PKG and inhibition of PKA L Santschi, M Reyes-Harde, PK Stanton Journal of neurophysiology 82 (3), 1577-1589, 1999 | 54 | 1999 |
| Children and CNS studies A Gage, M Haas GOOD CLINICAL PRACTICE JOURNAL 14 (10), 17, 2007 | | 2007 |
| COMBINING PROTEOMICS WITH GENETICS TO ELUCIDATE THE MOLECULAR MECHANISMS UNDERLYING NEURODEVELOPMENTAL AND NEUROPSYCHIATRIC DISEASES IN HUMAN NEURONS G Pintacuda, YH Hsu, JM Martín, A Ratanatharathorn, AX Maihofer, ... European Neuropsychopharmacology 51, e29-e30, 2021 | | 2021 |
| Combining Proteomics With Genetics to Elucidate the Molecular Mechanisms Underlying Posttraumatic Stress Disorder in Human Neurons K Eggan, G Pintacuda, K Tsafou, YH Hsu, J Martin, N Fornelos, ... Biological Psychiatry 89 (9), S11, 2021 | | 2021 |
| Correction: Chaby et al. Cross-Platform Evaluation of Commercially Targeted and Untargeted Metabolomics Approaches to Optimize the Investigation of Psychiatric Disease … LE Chaby, HC Lasseter, K Contrepois, RM Salek, CW Turck, A Thompson, ... Metabolites 13 (8), 933, 2023 | | 2023 |
| Cross-platform comparison of highly sensitive immunoassay technologies for cytokine markers: Platform performance in post-traumatic stress disorder and Parkinson’s disease HC Lasseter, AC Provost, LE Chaby, NP Daskalakis, M Haas, A Jeromin Cytokine: X 2 (2), 100027, 2020 | 37 | 2020 |
| Cross-Platform Comparison of Immunoassay Technologies to Assess Cytokine Markers in Patients With Post-Traumatic Stress Disorder and Parkinson’s Disease H Lasseter, A Provost, N Daskalakis, L Chaby, M Haas, A Jeromin Biological Psychiatry 87 (9), S378, 2020 | | 2020 |